Safety, Tolerability, Pharmacokinetics and Target Engagement of GSK3858279 in Healthy Caucasian, Chinese and Japanese Participants

Inclusion Criteria

• Participants between 20 and 65 years of age inclusive, at the time of signing the informed consent.
• Volunteers who are overtly healthy as determined by medical evaluation including medical history, physical examination, laboratory tests, and cardiac monitoring.
• Participant capable of giving signed informed consent which includes compliance with the requirements and restrictions listed in the informed consent form (ICF) and in this protocol.
• Participants who have evidence of completed vaccination for Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) with an approved vaccine.
• Body weight within the range 45 - 100 killogram (kg) and body mass index (BMI) within the range 18-29.9 kg per meter square (/m2) (inclusive).
• Japanese participants are eligible based on meeting all of the following:
• Participants born in Japan
• Descendants of four ethnic Japanese grandparents and two ethnic Japanese parents.
• Have lived outside Japan for less than ( )1.5 times upper limit of normal (ULN) .
• Bilirubin >1.5 times ULN (isolated bilirubin >1.5 times ULN is acceptable if bilirubin is fractionated and direct bilirubin 450 milliseconds (msec).
• History of Stevens Johnson Syndrome.
• Known immunodeficiency.
• Participants with a chronic infection (for example [e.g.], osteomyelitis), who have been receiving treatment within three months prior to dosing or individuals with an active infection.
• Previous or current history of bleeding diathesis, excessive bleeding or coagulation disorders.
• History of significant medical illness in the opinion of the investigator would interfere with the study procedures and / or assessments.
• Intended use of over-the-counter or prescription medication including herbal medications within 7 days prior to dosing until final follow-up visit.
• Live vaccine(s) or plans to receive such vaccines within 1 month of screening until final follow-up visit.
• Treatment with biologic agents (such as monoclonal antibodies including marketed drugs) within 3 months or 5 half-lives (whichever is longer) prior to dosing.
• Treatment with antiplatelet or anticoagulant agents within 7 days of dosing.
• Major surgery (as per investigator's judgement) within 3 months prior to dosing.
• Participation in the study would result in loss of blood or blood products in excess of 500 milliliters (mL) within 3 months.
• Exposure to more than 4 new chemical entities within 12 months prior to the first dosing day.
• Current enrolment or past participation in any other clinical study involving an investigational drug intervention within the last 3 months or 5 half-lives (whichever is longer) of signing the ICF.
• Presence of Hepatitis B surface antigen (HBsAg) at screening.
• Presence of the Hepatitis B core antibody (HBcAb) at screening.
• Positive Hepatitis C antibody test result at screening.
• Positive Hepatitis C Ribonucleic acid (RNA) test result at screening or within 3 months prior to first dose of study intervention.
• Abnormal clinically significant echocardiogram at screening, as assessed by the investigator.
• Cardiac troponin or N-terminal pro B-type natriuretic peptide (NT-proBNP) levels out of normal range at screening.
• Positive pre-study drug/alcohol screen.
• Positive human immunodeficiency virus (HIV) antibody test.
• Positive coronavirus disease 2019 (COVID-19): SARS-CoV2 polymerase chain reaction (PCR) or lateral flow test of a combined throat and nasopharyngeal swab or nasal swab only.
• Regular alcohol consumption within 6 months prior to the study defined as: an average weekly intake of >14 units for males and >14 units for females. One unit is equivalent to 8 grams of alcohol: a half-pint (approximately 240 mL) of beer, 1 glass (125 mL) of wine or 1 (25 mL) measure of spirits.
• Regular use of known drugs of abuse.
• Sensitivity to any of the study interventions, or components thereof, or drug or other allergy that, in the opinion of the investigator or medical monitor, co